课题基金 / 基金详情

Kruppel-like Factor and Maturation of hESC/hiPSC Derived Cardiomyoctyes

Kruppel-like Factor and Maturation of hESC/hiPSC Derived Cardiomyoctyes
Kruppel 样因子和 hESC/hiPSC 来源的心肌细胞的成熟
批准号:
8386169
负责人:
MARK MERCOLA
金额:
$29.25万
依托单位国家:
美国
项目类别:
财政年份:
2012
资助国家:
美国
项目状态:
已结题
起止时间:
2012-07-12 至 2014-06-30

项目摘要

项目成果

MARK MERCOLA的其他基金

相似基金

相关文献

中文摘要
翻译
描述(由申请人提供):该R21提案旨在确定Kr <$ppel样因子(KLF)是否促进干细胞衍生的心肌细胞的功能成熟,并建立成熟效应的生理和分子遗传基础。实现hESC和hiPSC衍生的心肌细胞用于药物发现、研究和心肌再生的前景的一个重要障碍是干细胞衍生的心肌细胞表现出胎儿细胞而不是成体细胞的电和机械特性。重要的是,未成熟的心肌细胞不产生成熟心肌细胞的力,并且它们的电特性在移植环境中是潜在的致心律失常的。此外,不成熟的离子通道和生理特性降低了体外分析的预测价值,例如用于评估候选药物的不良心脏作用。尽管现在已经有了从干细胞中获得心肌细胞的有效方法,但即使是最好的方法也只能产生不成熟的胎儿样细胞,因为只有很少的细胞能被移植到心肌细胞中。 我们知道指导成熟的信号。数据显示的高通量评估电生理成熟的仪器和软件的发展。使用这种技术,我们提供了初步的证据,KLF可以促进电和离子通道的成熟hESC衍生的和新生大鼠心室心肌细胞。本提案的具体目标是:1)通过离子通道和泵的功能表达、药物敏感性分析、动作电位和钙处理指标、收缩装置结构和力产生来定义KLF诱导的成熟; 2)建立生理效应的分子遗传学基础,部分通过质谱和下一代ChIPSeq分析确定KLF的结合配偶体和基因靶点。促进心肌细胞成熟的信号的识别应该导致用于获得功能性心肌细胞的改进方法,这将使许多干细胞应用于基础和应用研究。此外,引导外源性或内源性干细胞来源的能力对于实现心脏的功能性再生将是必不可少的。 公共卫生相关性:该项目旨在鉴定和表征指导心肌细胞从干细胞生理成熟的蛋白质和基因。来源于干细胞的心肌细胞通常缺乏对许多研究和临床应用重要的成体心肌细胞的电和机械特性。这些发现将构成概念上的进步,因为人们对生理成熟是如何控制的知之甚少,并将增加干细胞衍生的心肌细胞在研究和医学应用中的价值。
英文摘要
DESCRIPTION (provided by applicant): This R21 proposal is to determine if Kr¿ppel-like factors (KLFs) promote functional maturation of stem cell- derived cardiomyocytes, and to establish the physiological and molecular genetic basis for the maturational effects. An important impediment to realizing the promise of hESC and hiPSC-derived cardiomyocytes for drug discovery, research and myocardial regeneration is that stem cell-derived cardiomyocytes exhibit electrical and mechanical properties of fetal, rather than adult, cells. Critically, immatue cardiomyocytes do not generate the force of mature myocytes, and their electrical properties are potentially arrhythmogenic in a transplant setting. Moreover, immature ion channel and physiological properties diminish the predictive value of in vitro analyses such as for assessing adverse cardiac effects of drug candidates. Although efficient protocols are now used to derive cardiomyocytes from stem cells, even the best yield immature, fetal-like cells since very little is known about the signals that direct maturation. Data are presented showing the development of instrumentation and software for high throughput assessment of electrophysiological maturation. Using this technology, we provide preliminary evidence that KLFs can promote electrical and ion channel profile maturation of hESC-derived and neonatal rat ventricular cardiomyocytes. The specific aims of this proposal are to: 1) define the KLF-induced maturation by functional expression of ion channels and pumps, drug sensitivity profiling, action potential and calcium handling metrics, contractile apparatus structure, and force generation; and 2) establish the molecular genetic basis for the physiological effects, in part by determining the binding partners and gene targets of KLFs by mass spectroscopic and next generation ChIPSeq analyses. The identification of signals that promote cardiomyocyte maturation should lead to improved methods for deriving functional cardiomyocytes that will be enabling for many stem cell applications in basic and applied research. Moreover, the ability to direct exogenous or endogenous stem cell sources will be essential to achieve functional regeneration of the heart. PUBLIC HEALTH RELEVANCE: This project is to identify and characterize proteins and genes that direct physiological maturation of heart muscle cells from stem cells. Heart muscle cells derived from stem cells typically lack electrical and mechanical properties of adult cardiomyocytes that are important for many research and clinical applications. The findings will constitute a conceptual advance since little is known about how physiological maturation is controlled, and will increase the value of stem cell-derived cardiomyocytes for research and medical applications.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
hiPSC Modeling of Restrictive Cardiomyopathy for Drug Testing
  • 批准号:
    10716393
  • 项目类别:
  • 资助金额:
    $57.24万
  • 财政年份:
    2023
  • 负责人:
    MARK MERCOLA
  • 依托单位:
High throughput platform for simultaneous multiparametric assessment of cardiac physiology for heart failure drug development
  • 批准号:
    10745000
  • 项目类别:
  • 资助金额:
    $46.32万
  • 财政年份:
    2023
  • 负责人:
    MARK MERCOLA
  • 依托单位:
Targeting the genotype to phenotype link in HCM as a therapeutic strategy
  • 批准号:
    10355529
  • 项目类别:
  • 资助金额:
    $58.56万
  • 财政年份:
    2021
  • 负责人:
    MARK MERCOLA
  • 依托单位:
Targeting the genotype to phenotype link in HCM as a therapeutic strategy
  • 批准号:
    10576285
  • 项目类别:
  • 资助金额:
    $58.33万
  • 财政年份:
    2021
  • 负责人:
    MARK MERCOLA
  • 依托单位:
海外基金